Tenente Inês M, Hayes Madeline N, Ignatius Myron S, McCarthy Karin, Yohe Marielle, Sindiri Sivasish, Gryder Berkley, Oliveira Mariana L, Ramakrishnan Ashwin, Tang Qin, Chen Eleanor Y, Petur Nielsen G, Khan Javed, Langenau David M
Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, United States.
Harvard Stem Cell Institute, Cambridge, United States.
Elife. 2017 Jan 12;6:e19214. doi: 10.7554/eLife.19214.
Rhabdomyosarcoma (RMS) is a pediatric malignacy of muscle with myogenic regulatory transcription factors MYOD and MYF5 being expressed in this disease. Consensus in the field has been that expression of these factors likely reflects the target cell of transformation rather than being required for continued tumor growth. Here, we used a transgenic zebrafish model to show that Myf5 is sufficient to confer tumor-propagating potential to RMS cells and caused tumors to initiate earlier and have higher penetrance. Analysis of human RMS revealed that MYF5 and MYOD are mutually-exclusively expressed and each is required for sustained tumor growth. ChIP-seq and mechanistic studies in human RMS uncovered that MYF5 and MYOD bind common DNA regulatory elements to alter transcription of genes that regulate muscle development and cell cycle progression. Our data support unappreciated and dominant oncogenic roles for MYF5 and MYOD convergence on common transcriptional targets to regulate human RMS growth.
横纹肌肉瘤(RMS)是一种发生于儿童的肌肉恶性肿瘤,在这种疾病中会表达肌源性调节转录因子MYOD和MYF5。该领域的共识是,这些因子的表达可能反映了转化的靶细胞,而不是肿瘤持续生长所必需的。在这里,我们使用转基因斑马鱼模型表明,Myf5足以赋予RMS细胞肿瘤增殖潜能,并导致肿瘤更早发生且具有更高的发生率。对人类RMS的分析显示,MYF5和MYOD相互排斥表达,且二者都是肿瘤持续生长所必需的。对人类RMS进行的染色质免疫沉淀测序(ChIP-seq)和机制研究发现,MYF5和MYOD结合共同的DNA调控元件,以改变调节肌肉发育和细胞周期进程的基因的转录。我们的数据支持了MYF5和MYOD在共同转录靶点上汇聚以调节人类RMS生长的未被重视的主要致癌作用。